|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
T2 Biosystems, Inc. (TTOO) |
|
|
$0.17 0.00 (0.00%) as of 4:30 Thu 10/12
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
16,340,000 |
| Market
Cap: |
2.84(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0623 - $0.5911 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile T2 Biosystems is an in vitro diagnostics company and engaged in the detection of sepsis-causing pathogens and antibiotic resistance genes. Co.'s products include: T2Dx® Instrument, which runs diagnostic tests from patient samples; T2Candida® Panel, which is a direct-from-blood test that identifies the lethal form of blood stream infections that cause sepsis candidemia; T2Bacteria® Panel, which is a direct-from-blood test that detects bacterial pathogens associated with sepsis; T2Resistance® Panel, which is a direct-from-blood test that detects resistance genes from both gram-positive and gram-negative pathogens; and T2SARS-CoV-2™ Panel, which detect SARS-CoV-2, the coronavirus in patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
48,345,798 |
48,364,599 |
| Total Sell Value |
$0 |
$0 |
$12,851,221 |
$12,864,540 |
| Total People Sold |
0 |
0 |
1 |
5 |
| Total Sell Transactions |
0 |
0 |
8 |
18 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gibbs Michael Terrence |
General Counsel |
• – – |
2022-02-24 |
4/A |
D |
$0.45 |
$34,498 |
D/D |
(76,867) |
148,775 |
|
- |
|
| Gibbs Michael Terrence |
General Counsel |
• – – |
2022-02-24 |
4/A |
OE |
$0.00 |
$0 |
D/D |
145,719 |
225,642 |
|
- |
|
| Gibbs Michael Terrence |
General Counsel |
• – – |
2022-02-24 |
4 |
D |
$0.45 |
$34,498 |
D/D |
(76,867) |
138,775 |
|
- |
|
| Gibbs Michael Terrence |
General Counsel |
• – – |
2022-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
145,719 |
215,642 |
|
- |
|
| Sprague John M |
Chief Financial Officer |
• – – |
2022-02-24 |
4 |
D |
$0.45 |
$24,688 |
D/D |
(55,008) |
136,196 |
|
- |
|
| Sprague John M |
Chief Financial Officer |
• – – |
2022-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
145,719 |
191,204 |
|
- |
|
| Sperzel John J Iii |
See Remarks |
• • – |
2022-02-24 |
4 |
D |
$0.45 |
$63,532 |
D/D |
(141,560) |
191,773 |
|
- |
|
| Sperzel John J Iii |
See Remarks |
• • – |
2022-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
333,333 |
333,333 |
|
- |
|
| Sprague John M |
Chief Financial Officer |
• – – |
2022-02-21 |
4/A |
D |
$0.47 |
$1,759 |
D/D |
(3,775) |
51,639 |
|
- |
|
| Gibbs Michael Terrence |
General Counsel |
• – – |
2022-02-21 |
4/A |
D |
$0.47 |
$2,458 |
D/D |
(5,275) |
79,923 |
|
- |
|
| Gibbs Michael Terrence |
General Counsel |
• – – |
2022-02-21 |
4/A |
OE |
$0.00 |
$0 |
D/D |
10,000 |
85,198 |
|
- |
|
| Sprague John M |
Chief Financial Officer |
• – – |
2022-02-21 |
4 |
D |
$0.47 |
$1,759 |
D/D |
(3,775) |
45,485 |
|
- |
|
| Sprague John M |
Chief Financial Officer |
• – – |
2022-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
55,414 |
|
- |
|
| Gibbs Michael Terrence |
General Counsel |
• – – |
2022-02-21 |
4 |
D |
$0.47 |
$2,458 |
D/D |
(5,275) |
69,923 |
|
- |
|
| Gibbs Michael Terrence |
General Counsel |
• – – |
2022-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
75,198 |
|
- |
|
| Ahuja Aparna |
Chief Medical Officer |
• – – |
2022-01-06 |
4 |
AS |
$0.48 |
$29,754 |
D/D |
(61,988) |
107,611 |
|
-53% |
|
| Ahuja Aparna |
Chief Medical Officer |
• – – |
2022-01-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
153,664 |
169,599 |
|
- |
|
| Toft Robin |
Director |
– • – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,258 |
54,985 |
|
- |
|
| Elsbree David B |
Director |
– • – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,258 |
202,981 |
|
- |
|
| Saunders Ninfa |
Director |
– • – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,258 |
54,985 |
|
- |
|
| Liebman Seymour |
Director |
– • – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,258 |
161,897 |
|
- |
|
| Bernard Thierry |
Director |
– • – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,258 |
54,985 |
|
- |
|
| Toft Robin |
Director |
– • – |
2021-08-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,727 |
22,727 |
|
- |
|
| Saunders Ninfa |
Director |
– • – |
2021-08-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,727 |
22,727 |
|
- |
|
| Bernard Thierry |
Director |
– • – |
2021-08-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,727 |
22,727 |
|
- |
|
350 Records found
|
|
Page 4 of 14 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
